Executive Summary: Aziyo Biologics, Inc. (AZYO)
Business Context and Reporting Period
This Form 8-K, dated June 20, 2022, reports a significant executive transition at Aziyo Biologics, Inc. (AZYO). The filing details the appointment of C. Randal Mills, Ph.D., as Interim President and Chief Executive Officer, effective June 21, 2022, succeeding Ronald Lloyd. The report also addresses a temporary noncompliance with Nasdaq listing rules regarding Audit Committee composition.
Key Financial Metrics and Compensation
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or debt levels. However, it discloses specific compensation figures related to the executive transition:
- Dr. Mills Compensation: Annual base salary of $600,000 with a target annual bonus of 60% ($360,000), guaranteed for the first 12 months.
- Dr. Mills Equity: Grant of 456,278 stock options and 224,734 restricted stock units (RSUs), with vesting tied to time and specific share price thresholds ($12.50, $17.00, $25.00, and $37.00).
- Mr. Lloyd Severance: Eligible for 12 months of base salary plus 100% of the annual target bonus upon separation. A potential additional cash bonus of up to $1,000,000 is contingent on performance goals.
- RSU Make-Whole Payment: A potential lump sum payment to Mr. Lloyd equal to the difference between $279,656 and the fair market value of 39,894 vested RSUs as of September 8, 2022.
Material Changes and Corporate Governance
The primary material change is the departure of Ronald Lloyd as CEO and Board member. Concurrently, Dr. Mills ceased serving on the Audit Committee and Compensation Committee to assume the CEO role. This transition resulted in the Audit Committee falling below the minimum requirement of three independent directors under Nasdaq Listing Rule 5605(c)(2). The Company notified Nasdaq of this noncompliance and has a 180-day cure period to appoint a new independent director to regain compliance.
Outlook, Risks, and Contingencies
Management Commentary: The Company intends to appoint a third independent director to the Audit Committee prior to the end of the 180-day cure period to satisfy Nasdaq requirements. Dr. Mills' interim role is set for 90 days, with the possibility of extension or conversion to a permanent role based on Board determination.
Risks and Contingencies:
- Listing Compliance: Risk of delisting if the Company fails to appoint a qualified independent director within the 180-day cure period.
- Equity Vesting: A significant portion of Dr. Mills' equity compensation is performance-based, contingent on the Company achieving specific share price milestones.
- Severance Liability: The Company faces potential cash outflows for Mr. Lloyd's severance, including a performance-based bonus up to $1,000,000 and potential change-in-control enhancements.
Investor Verification Checklist
- Verify the Company's progress in appointing a new independent director to the Audit Committee to ensure continued Nasdaq listing compliance.
- Review the specific performance goals required for Mr. Lloyd to receive the up to $1,000,000 bonus.
- Monitor the Company's share price relative to the vesting thresholds ($12.50, $17.00, $25.00, $37.00) for Dr. Mills' equity grants.
- Confirm the status of the "Interim Period" for Dr. Mills and whether the Board has extended his tenure or appointed a permanent CEO.